… after adjustment for age and smoking status with an HR of 2.5 that was highly significant (22). …
There was an HR of 0.93 per 1-unit increase in BMI. The reason for the protective effect of …

Background: Ventilator-associated pneumonia (VAP) is the most common nosocomial infection
in critically ill patients. The clinical and economic consequences of VAP are unclear, with …

Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease.
Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is …

This document is an international evidence-based guideline on the diagnosis and management
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …

Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …

Background: In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS)
classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, …

Background: This document provides clinical recommendations for the diagnosis of
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …

… The HR for mortality with ambrisentan after a median follow-up of 52 weeks was 2.08 (95%
CI, 0.75–5.76; low confidence). Ambrisentan increased disease progression, assessed as …

The natural history of idiopathic pulmonary fibrosis (IPF) has been characterized as a steady,
predictable decline in lung function over time. Recent evidence suggests that some …

Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically
significant, respiratory deterioration of unidentifiable cause. The objective of this …